Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypercholesterolemia - Overview
Hypercholesterolemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hypercholesterolemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypercholesterolemia - Companies Involved in Therapeutics Development
Hypercholesterolemia - Drug Profiles
Hypercholesterolemia - Dormant Projects
Hypercholesterolemia - Discontinued Products
Hypercholesterolemia - Product Development Milestones
Featured News & Press Releases
Sep 23, 2022: Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
Sep 21, 2022: Verve Therapeutics announces clearance of clinical trial authorisation application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in patients with heterozygous familial hypercholesterolemia
Sep 13, 2022: MediciNova receives a notice of allowance for a new patent covering MN-001 and MN-002 for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia in Cada
Aug 29, 2022: New Amgen data at ESC 2022 show long-term LDL-C lowering with REPATHA (evolocumab) was well-tolerated for more than 8 years
Aug 29, 2022: NewAmsterdam Pharma showcases leadership in cardiometabolic disease treatment in multiple presentations at ESC congress 2022
Aug 29, 2022: Verve Therapeutics highlights preclinical data supporting nomition of VERVE-201 ANGPTL3 product candidate at the European Society of Cardiology 2022 Congress
Aug 29, 2022: AMGEN to present new data at ESC Congress 2022 highlighting up To 8.5 years of Repatha (Evolocumab) safety and tolerability data in high-risk ASCVD patient populations
Aug 29, 2022: Latest simulation alyses from the SANTORINI registry indicates that adding bempedoic acid in the lipid lowering treatment algorithm might help more patients achieve LDL-C recommended goals
Aug 02, 2022: Vaxxinity’s anti-PCSK9 candidate demonstrates durable LDL cholesterol lowering in non-human primates
Jul 28, 2022: NewAmsterdam pharma doses first patient in phase 3 BROOKLYN clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia
Jul 12, 2022: Verve Therapeutics doses first human with an investigatiol in vivo base editing medicine, VERVE-101, as a potential treatment for heterozygous familial hypercholesterolemia
Jun 29, 2022: Nyrada announces update on Cholesterol-Lowering Program
Jun 13, 2022: Innovent announces the NMPA acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)
May 31, 2022: First Subject dosed in Lipigon’s phase I clinical study with antisense oligonucleotide Candidate Derived from Secar Pharmaceutical’s Lplus(TM) Technology Platform
May 21, 2022: Evkeeza (evicumab) phase 3 trial demonstrates 48% LDL-C reduction in children with ultra-rare form of high cholesterol
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Hypercholesterolemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Hypercholesterolemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hypercholesterolemia - Dormant Projects, 2022
Hypercholesterolemia - Dormant Projects, 2022 (Contd..1)
Hypercholesterolemia - Dormant Projects, 2022 (Contd..2)
Hypercholesterolemia - Dormant Projects, 2022 (Contd..3)
Hypercholesterolemia - Dormant Projects, 2022 (Contd..4)
Hypercholesterolemia - Dormant Projects, 2022 (Contd..5)
Hypercholesterolemia - Discontinued Products, 2022
Hypercholesterolemia - Discontinued Products, 2022 (Contd..1)